Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
CheckMate 577 Final Results: Adjuvant Nivolumab Sustains Disease-Free ...
Adherence to CheckMate 577 Within a Community Health Care System in the ...
CheckMate 577 study on nivolumab for gastro-oesophageal cancer ...
Checkmate 577 - Is Nivolumab adjuvant the standard of care in esophagus ...
CheckMate 577: Adjuvant Nivolumab Plus Neoadjuvant CRT for Esophageal ...
CheckMate 577: nivolumabe adjuvante após quimioradioterapia e cirurgia ...
CheckMate 77T Trial: Perioperative Nivolumab Plus Chemotherapy in Stage ...
CheckMate 577: final OS results of adjuvant nivolumab in EC/GEJC ...
ASCO 2025 | Dr. Wentao Fang on CheckMate 577: Adjuvant Immunotherapy ...
ESOPEC, CheckMate 577, and Neo-AEGIS: Breakthroughs in Esophageal ...
(PDF) First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate ...
陳奇勳教授專訪 | CheckMate -577數據更新證實長期獲益，納武利尤單抗問鼎食管癌輔助治療 - 每日頭條
Subcutaneous Nivolumab Preferred Over IV for ccRCC: PROs From CheckMate ...
CheckMate 77T QOL Data Further Support Perioperative Nivolumab in ...
Hematología y Oncología: ASCO 2015 - CheckMate 067: Improved PFS with ...
(PDF) Checkmate 274 trial: Is Nivolumab the new standard in adjuvant ...
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 ...
CheckMate 77T Trial of Perioperative Nivolumab Generates EFS Benefit in ...
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent ...
Final CheckMate 9ER data show long-term efficacy of nivolumab ...
Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early ...
CheckMate 017/057的五年生存结果：Nivolumab在二线非小细胞肺癌治疗中优于多西他赛 - 精选 - 阳光肺科
| Comparisons between the CheckMate 227 trial and simulation, overall ...
CheckMate 274: 5-year data confirm durable benefit with nivolumab ...
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and ...
Frontiers | Nivolumab adjuvant therapy for esophageal cancer: a review ...
傅剑华教授：CheckMate-577研究满载而归，开辟食管癌免疫辅助治疗全新道路_武利尤_患者_手术
局部晚期食管癌治疗指南更新解读 - 高龄备孕网
VÑ CheckMate-577, NeoAd CáEsóf UGE, R0, ady [Nivolumab vs Placebo ...
Journal of Clinical Images and Medical Case Reports
Milestones of PD-1 inhibition in gastric and esophageal cancer ...
Adjuvant Nivolumab in Patients with Resected Esophageal or GEJ Cancer ...
Landmark Trials in Carcinoma Esophagus management | PPTX
Adjuvant nivolumab in resected esophageal or gastroesophageal junction ...
DailyMed - OPDIVO QVANTIG- nivolumab and hyaluronidase-nvhy injection ...
CheckMate-577 opens a new perspective for the treatment of esophageal ...
CheckMate-577: Nivolumab Adjuvant Therapy in Patients with Resected ...
Nivolumab for perioperative esophageal and gastroesophageal cancer ...
食道がんへの術後ニボルマブ、長期追跡でもベネフィット示す（CheckMate 577）／ASCO2025｜医師向け医療ニュースはケアネット
陈奇勋教授：CheckMate-577 研究独树一帜，纳武利尤单抗引领食管癌辅助治疗全新格局_患者_手术_免疫
2021食管癌诊疗年度盘点：免疫时代的治疗选择_研究_患者_化疗
Nivolumab plus chemotherapy in first-line metastatic non-small-cell ...
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With ...
食道がんのニボルマブ術後補助療法、追加解析の成績（CheckMate 577）／ASCO2021｜医師向け医療ニュースはケアネット
CheckMate-77T: A Deeper Look at a Nivolumab-Based Regimen in NSCLC ...
Oncology me
Nivolumab in metastatic urothelial carcinoma after platinum therapy ...
Efficacy and safety of nivolumab in the treatment of non-small cell ...
(PDF) A population-based study in resected esophageal or ...
PD-1最新临床进展大公开|NSCLC|ORR|PFS|临床|肺癌|化疗|-健康界
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus ...
Nivolumab with or without ipilimumab in patients with recurrent or ...
Q&A with Ronan J. Kelly: FDA Approval of Immunotherapy Drug Nivolumab ...
【4332】ASCO|Ronan Kelly教授深度解析CheckMate 577长随访数据，展望食管癌围手术期免疫治疗未来之路医药新闻 ...
CheckMate-77T ｜术前术后应用纳武利尤单抗降低 NSCLC 术后复发风险_凤凰网健康_凤凰网
PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC ...
Nivolumab may be ‘new standard’ in esophageal, gastroesophageal ...
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma ...
Nivolumab in Patients With Advanced or Metastatic Malignancies ...
Extended CheckMate-274 Data Reinforce the Benefit of Adjuvant Nivolumab ...
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes ...
A population-based study in resected esophageal or gastroesophageal ...
Evaluation of Two Dosing Regimens for Nivolumab in Combination With ...
Health-related Quality of Life with Adjuvant Nivolumab After Radical ...
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in ...
Society of Urologic Oncology - DISEASE-FREE SURVIVAL WITH LONGER FOLLOW ...
Highlights zu den Tumoren des oberen Gastrointestinaltrakts - Onkologie ...
ESMO 2022: Tumor and Immune Features Associated with Disease-Free ...
Checkpoint Inhibitors Gain Traction in the Frontline Setting for ...
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of ...
Overall Survival in Patients With Advanced Melanoma Who Received ...
Nivolumab versus standard, single-agent therapy of investigator's ...
CheckMate-77T Update: Nivolumab-Based Regimen Improves EFS in NSCLC
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced ...
Daniel P. Petrylak | New Targets for Advanced Bladder Cancer
